The munKNEE Psychedelic Drug Stocks Index tracks 6 psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them), and have market capitalizations in excess of $50M (but some are still penny stocks). This article highlights their performances over the past week, in descending order, and for the past 3 weeks and the extent to which each company is likely to encounter financial stress and/or bankruptcy in the next 2 years compared to its peers according to their Altman Z-Scores (as sourced from macroaxis.com).

1. Atai (ATAI): UP 11.6% last week; UP 2.3% in the last 3 weeks
   • Is focused on acquiring and developing treatments that lead to paradigm shifts in the mental health space.
   • has a <3% chance of encountering financial stress in the next 2 years
2. Cybin (CYBN): DOWN 4.3% last week; DOWN 6.4% in the last 3 weeks
   • Is focused on utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.
   • has a +77% chance of encountering financial stress in the next 2 years.
3. GH Research (GHRS): DOWN 4.5% last week; DOWN 0.2% in the last 3 weeks
   • Is focused on developing 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
   • has a +73% chance of encountering financial stress in the next 2 years.
4. Mind Medicine (MNMD): DOWN 6.2% last week; DOWN 10.3% in the last 3 weeks
   1. Is focused on discovering, developing, and deploying therapies to address addiction and mental illness development.
   2. has a +77% chance of encountering financial stress in the next 2 years.
5. Compass Pathways (CMPS): DOWN 9.9% last week; DOWN 9.4% in the last 3 weeks
   • Is focused on the development of psilocybin therapy for people with Treatment-Resistant Depression.
   • has a +77% chance of encountering financial stress in the next 2 years.
6. Seelos (SEEL): DOWN 12.8% last week; DOWN 6.8% in the last 3 weeks
   • Is focused on developing products for the treatment of Central Nervous System disorders and other rare disorders.
   • has a +56% chance of encountering financial stress in the next 2 years.

In total, the Index went DOWN 5.5%, on average, last week and DOWN 6.0% since the end of October.

Six (6) other psychedelic companies are primarily focused on the development, expansion, and operation of ketamine-assisted therapy (KAT) clinics hoping to capitalize on the massive commercial opportunity that exists to treat the two billion people worldwide who suffer from chronic pain, addiction, and substance abuse withdrawal, and depression. All are highly speculative investments and penny stocks with tiny market capitalization and are identified below with a description of each of their commercialization developments:

1. Awakn Life Sciences Corp.  (NEO: AWAKN|OTCQB: AWKNF)
   • Is concentrating on the treatment of Alcohol Use Disorder (AUM)
     • has 3 KAT clinics, 2 in the U.K. and 1 in Norway and
     • is developing MDMA-assisted therapy for AUM
   •  Is also in the process of developing KAT for Gambling Disorder
   • Go here for the company's latest quarterly (Q2) financial results
2. Delic Corp. (CSE: DELC|OTCQB: DELCF)
   • Has 13 ketamine-assisted therapy (KAT) clinics in the U.S.
3. Field Trip Health and Wellness Ltd. (TSXV: FTHW|OTCQB: FTHWF)
   • Is concentrating on therapies for the treatment of resistant depression, post-traumatic stress disorder and disorders affecting the central nervous systems
   • Operates KAT clinics in Canada (3), the U.S. (8) and Europe (1)
4. Numinus Wellness Inc. (TSX: NUMI|OTCQX: NUMIF)
   • has 3 KAT clinics in Canada;
   • has the ability to undertake treatments using psilocybin and MDMA in Canada as authorized by Health Canada's Special Access Program
   • Has 6 KAT clinics in Utah and 2 in Arizona
5. Revitalist Lifestyle and Wellness Ltd. (CSE: CALM|OTCQB: RVLWF)
   • Has 10 KAT clinics in 6 states and 9 options on other clinics
6. Universal Ibogaine Inc. (TSXV: IBO|OTCQB: IBOGF)
   • Is concentrating on the treatment of Opioid Use Disorder using ibogaine which has a “Prescription Drug List” status in Canada (vs. Schedule 1 in the U.S.) facilitating research and development toward medicalization

The above psychedelic-assisted therapy clinic stocks went DOWN 1.5%, on average, last week but remain unchanged since the end of October.

More By This Author:

Major Canadian Cannabis LP Stocks' Financial Metrics: A Comparison
Plant-Based Food Stocks Index Down Again This Week
A Comparison Of Major American MSO Cannabis Stocks' Q3 Metrics